Seattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in a heavily pre-treated group of patients with advanced disease.
NICE may be 20 this year, but its policy on end-of-life (EoL) treatments – where NICE can recommend a treatment at around £50,000 per Quality Adjusted Life Year (QALY) – is a young policy i
